← Back
Data updated: May 24, 2026
RECORDATI RARE
Big Pharma Pharmaceuticals
RECORDATI RARE is a major pharmaceutical company with 12 FDA-approved products.
1949
Since
12
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
8 Small Molecules
Novel Drugs (2020):
1 Novel Approvals 1 First-in-Class 1 Orphan Drug
Key Drugs
Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.
Recent FDA Approvals
New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.
No recent approvals
Therapeutic Areas
Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.
No indication data
Pipeline Snapshot
Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (0)
Company Info
- First Approval
- 1949-03-15
- Latest
- 2025-11-04
- Applications
- 12